Innovative mental health medicines

Biopharmaceutical drug discovery
Unique proprietary mental health medicines
Accelerated regulatory pathways
Patients with urgent and unmet needs

Our Target

PHARMACEUTICAL: KRN-101

A Psilocybin-based medicine derived from mycelium extracts, manufactured with our patented bioreactor technology

Natural
Standardized
Safe
Effective

LEAD INDICATION: CANCER-RELATED ANXIETY

No current treatment - unmet need
Fast expansion to addiction and PTSD
Access to early revenue in UK (through Real World Evidence)
Estimated revenue per patient $7,500
Patients currently suffering:
- UK = 1 million
- USA = 6 million
- EU = 7 million

In the Media

“Psilocybin-assisted therapy is one of the most promising innovations for the treatment of depression seen for decades”

Stock & Sector Performance

ABRT vs. Peers

Stoic Report (Oct 22)

Psychedelics Index June

October 2022

Key Assets

Value created from $4.7 million Series A raise

Canada

Health Canada licensed lab
Government approved supplier (SAP)
Patent-protected bioreactor technology
In-house analytics
Fungi master cell-bank

Portugal

GLP certified analytical and manufacturing lab
Scheduled substance license
Toxicological (animal) testing facility
KRN-101 manufacture for global distribution

UK

Expert Clinical Advisory Board
Partnership with Manchester University
RWE Trial prepared - endorsed by National Cancer Research Institute (NCRI)
Clinical trial sites engaged
Patient pools identified

Australia

First In-Human Studies
KRN-101 available for late-stage clinical trials
43.5% cash rebate on all expenditure from Australian Govt.
Industry-leading partnerships

Accomplished Management Team

Previous experience...

Next Steps:
Value Milestones

Pre-Clinical Studies Completed (Q4 2022)

KRN-101 ready for regulatory submissions and available for licensing
In-Human Study (Q2/Q3 2023)

32 Patients
43.5% rebate of all costs from Australian Govenment
RWE Clinical Trial Initiation (Q4 2023)

~250 patients
Cancer-related Distress
Phase 2b (MHRA)
FDA Application (Q4 2023)

Phase 2b (FDA)
Submissions for further trials in the US market

Clinical development programme with comparable valuations

Invest in a breakthrough technology for mental health

Reserve your shares…

Contact us directly for discounted shares

CANADIAN SECURITIES EXCHANGE RULES HAVE CHANGED

Click here to access our investor documents